Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission

Brentuximab vedotin monotherapy for late‐relapse CHL is a promising therapeutic with sustained CR benefit and avoiding potential toxicities caused by aPBSCT/HDT.

Detalles Bibliográficos
Autores principales: Nagashima, Kana, Kikuchi, Shohei, Iyama, Satoshi, Fujita, Chisa, Goto, Akari, Horiguchi, Hiroto, Kobune, Masayoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069848/
https://www.ncbi.nlm.nih.gov/pubmed/32185037
http://dx.doi.org/10.1002/ccr3.2688
_version_ 1783505850479935488
author Nagashima, Kana
Kikuchi, Shohei
Iyama, Satoshi
Fujita, Chisa
Goto, Akari
Horiguchi, Hiroto
Kobune, Masayoshi
author_facet Nagashima, Kana
Kikuchi, Shohei
Iyama, Satoshi
Fujita, Chisa
Goto, Akari
Horiguchi, Hiroto
Kobune, Masayoshi
author_sort Nagashima, Kana
collection PubMed
description Brentuximab vedotin monotherapy for late‐relapse CHL is a promising therapeutic with sustained CR benefit and avoiding potential toxicities caused by aPBSCT/HDT.
format Online
Article
Text
id pubmed-7069848
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-70698482020-03-17 Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission Nagashima, Kana Kikuchi, Shohei Iyama, Satoshi Fujita, Chisa Goto, Akari Horiguchi, Hiroto Kobune, Masayoshi Clin Case Rep Case Reports Brentuximab vedotin monotherapy for late‐relapse CHL is a promising therapeutic with sustained CR benefit and avoiding potential toxicities caused by aPBSCT/HDT. John Wiley and Sons Inc. 2020-01-31 /pmc/articles/PMC7069848/ /pubmed/32185037 http://dx.doi.org/10.1002/ccr3.2688 Text en © 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Nagashima, Kana
Kikuchi, Shohei
Iyama, Satoshi
Fujita, Chisa
Goto, Akari
Horiguchi, Hiroto
Kobune, Masayoshi
Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission
title Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission
title_full Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission
title_fullStr Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission
title_full_unstemmed Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission
title_short Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission
title_sort successful brentuximab vedotin monotherapy against late relapse of classical hodgkin lymphoma 6 years after first remission
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069848/
https://www.ncbi.nlm.nih.gov/pubmed/32185037
http://dx.doi.org/10.1002/ccr3.2688
work_keys_str_mv AT nagashimakana successfulbrentuximabvedotinmonotherapyagainstlaterelapseofclassicalhodgkinlymphoma6yearsafterfirstremission
AT kikuchishohei successfulbrentuximabvedotinmonotherapyagainstlaterelapseofclassicalhodgkinlymphoma6yearsafterfirstremission
AT iyamasatoshi successfulbrentuximabvedotinmonotherapyagainstlaterelapseofclassicalhodgkinlymphoma6yearsafterfirstremission
AT fujitachisa successfulbrentuximabvedotinmonotherapyagainstlaterelapseofclassicalhodgkinlymphoma6yearsafterfirstremission
AT gotoakari successfulbrentuximabvedotinmonotherapyagainstlaterelapseofclassicalhodgkinlymphoma6yearsafterfirstremission
AT horiguchihiroto successfulbrentuximabvedotinmonotherapyagainstlaterelapseofclassicalhodgkinlymphoma6yearsafterfirstremission
AT kobunemasayoshi successfulbrentuximabvedotinmonotherapyagainstlaterelapseofclassicalhodgkinlymphoma6yearsafterfirstremission

Ejemplares similares